Tuesday, September 29, 2020

Invokana Diabetes Drug Causing Kidney and Heart Issues

A blockbuster diabetes drug called Invokana has pulled in hundreds of millions of dollars for Big Pharma, but the FDA recently announced that the treatment is causing even more problems in diabetics. Some of the major issues associated with Invokana include kidney damage, myocardial infarction (heart attacks), and ketoacidosis.Ring...

Popular Diabetes Medication Linked to Kidney Failure

Via America's Lawyer:According to latest data from the Centers for Disease Control, more than 29-million Americans suffer from diabetes, and nearly one of four people with the disease aren't even aware that they have it. Even worse, as many as 86-million Americans currently suffer from pre-diabetes, and if preemptive...

According to FDA, Invokana Increasing Risk of Osteoporosis

In addition to kidney damage, ketoacidosis and heart attacks, it turns out that canagliflozin – sold under the brand names Invokana and Invokamet – increases the risks of osteoporosis, or loss of bone density.In clinical studies, elderly Type-2 diabetics treated with Invokana for two years or more showed reduced...

Invokana Maker Turned Health Care Consumers into Guinea Pigs

If you were fully informed about the potential side effects of a medication, would you still choose to take it?This is the cause of action in the growing number of lawsuits against drug companies, such as those naming Janssen Pharmaceuticals and Mitsubishi Tanabe, the makers and sellers of the...

J&J Spent Nearly $20 million on “Perks” to Doctors and Hospitals to Promote Invokana

According to data from the U.S. Centers for Medicare and Medicaid, in 2014 Johnson & Johnson spent nearly $20 million on payments and various “perks” to doctors and hospitals to promote their diabetes drug Invokana. That’s some serious sugar Johnson & Johnson doled out, and it was enough to...

The Proof Is In: Invokana Puts Diabetic Patients at Greater Risk for Amputation

Last year, the European Medicines Agency (EMA) started an investigation into the possibility that use of the diabetic medication Invokana (canagliflozin) increased a patient's risk of limb amputation. Although solid evidence of this risk had not yet been found, the EMA chose to err on the side of caution,...

Manufacturer of Invokana Admits Link to Acute Kidney Injuries

Considering our government is bought and paid for by Big Pharma, it’s only fitting that Janssen Pharmaceuticals has used the Beltway’s time-honored “Friday news dump” to inform the public that its blockbuster diabetes medication, Invokana, causes kidney injuries when it quietly updated Invokana’s warning label on Friday, May 20,...

Despite Onslaught of Injury Lawsuits, Janssen Cuts Deal with European Distributor for Invokana

While injury lawsuits over the diabetic medication Invokana (canagliflozin) continue to pile up against Johnson & Johnson subsidiary Janssen Pharmaceuticals, the manufacturer has entered into a distribution agreement with U.K.-based Mundipharma, giving the British company exclusive rights to sell Invokana and Vokanamet (known as Invokamet in the U.S.) in...

Invokana and Amputation Risk: E.U. Health Authorities Now Require Package Warning

Last year (May 2016), the U.S. Food and Drug Administration issued an “advisory” to physicians regarding results of a continuing clinical trial indicating that use of the diabetes medication Invokana (canagliflozin) “may” increase the risk of lower limb amputations.This year, the European Medicines Agency (EMA) has ordered that...

Johnson & Johnson Moves Ahead in Seeking Approval For Expanded Use of Invokana

Despite the demonstrated links between lower limb amputations, kidney failure, osteoporosis and acute pancreatitis, Johnson & Johnson has followed through with its earlier plans to expand the market for its controversial diabetic medication, Invokana. This month, the New Jersey-based pharmaceutical giant filed a supplemental new drug application (SNDA) to...